Neuroleptic malignant syndrome-an 11-year longitudinal case-control study

Canadian Journal of Psychiatry

Volumn 57, Issue 8, 2012, Pages 512-518

  Nielsen, René Ernst ^a,b   Jensen, Signe Olrik Wallenstein ^a   Nielsen, Jimmi ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Regional Psychiatric Services West   (Denmark)

Author keywords

Mortality; Neuropsychiatry; Psychopharmacology; Psychosis; Risk factor

Indexed keywords

BENZODIAZEPINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTOR;

EID: 84873048656     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700810     Document Type: Article

References (44)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): APA; 2000.
2. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137-1145.
3. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143(10):1227-1233.
4. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005;135(3):249-256.
5. Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf. 2010;19(5):429-435.
6. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72:1222-1228.
7. MJ Bhanushali, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22(2):389-411.
8. Panagariya S, Sharma B, Singh R, et al. The neuroleptic malignant syndrome: a report of 14 cases from North India. Neurol India. 2007;55(2):166-168.
9. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18-25.
10. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870-876.
11. Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010;64(1):79-87.
12. Ananth J, Aduri K, Parameswaran S, et al. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatr. 2004;16:219-228.
13. Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005;252(11):1299-1306.
14. Viejo LF, Morales V, Punal P, et al. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand. 2003;107(1):45-49.
15. Berardi D, Dell'Atti M, Amore M, et al. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol. 2002;17(2):99-102.
16. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010;25(12):1780-1790.
17. Bilanakis N, Peritogiannis V, Kalampokis G. Infections as complications of neuroleptic malignant syndrome. World J Biol Psychiatry. 2009;10(4):973-976.
18. Choi-Kain LW, Pope HG. "Atypical" neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes. Harv Rev Psychiatry. 2007;15(4):181-186.
19. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. 2005;112(3):238-240.
20. StataCorp. Stata: release 11 [statistical software]. College Station (TX): Stata Corporation; 2009.
21. Sartorius N. [Classification of mental disorders according to ICD 10]. Encephale. 1995;21(Spec No 5):9-13. [Article in French].
22. Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82-84.
23. Munk-Joøgensen P, Ostergaard SD. Register-based studies of mental disorders. Scand J Public Health. 2011;39:170-174.
24. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268.
25. Denmark S. [IDA: an integrated database for labour market research]. Copenhagen (DK): Statistics Denmark Press; 1991. [Article in Danish].
26. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-448.
27. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2010 Nov 26; [Epub ahead of print].
28. World Health Organization (WHO). WHO collaborating centre for drug statistics methodology. ATC/DDD index. Geneva (CH): WHO; 2009.
29. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46(4):354-357.
30. Allebeck P. The use of population based registers in psychiatric research. Acta Psychiatr Scand. 2009;120(5):386-391.
31. Barr CE, Mednick SA, Munk-Jørgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch Gen Psychiatry. 1990;47(9):869-874.
32. Bock C, Bukh JD, Vinberg M, et al. Validity of the diagnosis of a single depressive episode in a case register. Clin Pract Epidemiol Ment Health. 2009;5:4.
33. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol. 2009;19(7):483-486.
34. Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry. 2001;58(11):1039-1046.
35. Qin P, Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch Gen Psychiatry. 2005;62(4):427-432.
36. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37(Suppl 1):S54-S64.
37. Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry. 1987;144(10):1344-1346.
38. Khan M, Farver D. Recognition, assessment and management of neuroleptic malignant syndrome. S D J Med. 2000;53(9):395-400.
39. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(4):464-470.
40. Heyland D, Sauve M. Neuroleptic malignant syndrome without the use of neuroleptics. CMAJ. 1991;145(7):817-819.
41. Addonizio G, Roth SD, Stokes PE, et al. Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis. 1988;176(11):682- 685.
42. Heberlein A, Bleich S, Kornhuber J, et al. [Benzodiazepine dependence: causalities and treatment options]. Fortschr Neurol Psychiatr. 2009;77(1):7-15. [Article in German].
43. Prochaska JJ, Gill P, Hall SE, et al. Identification and treatment of substance misuse on an inpatient psychiatry unit. Psychiatr Serv. 2005;56(3):347-349.
44. Hansen SS, Munk-Jørgensen P, Guldbaek B, et al. Psychoactive substance use diagnoses among psychiatric in-patients. Acta Psychiatr Scand. 2000;102(6):432-438.